About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
Targets, Treatments and Outcomes: Emerging Targets and Therapies in AH
By
Juan Pablo Arab
0 views
November 15, 2022
Comments
0
Login to view comments.
Click here to Login
Recommended
AUTOPLAY
ON
18:46
Houston Methodist Hospital
MAFLD: What Is It?
Feat.
D. Victor
43:23
MedNews Week
Best Practices In Managing NAFLD / NASH
Feat.
D. Bernstein
31:02
Scripps Health
Pharmacologic Management of Alcohol Use Disorder
Feat.
R. Lee
38:47
UPMC
The Fatty Liver Disease Epidemic
Feat.
M. Klinge
30:10
Michigan Medicine
Managing Alcohol Use Disorder in Patients with Liver Disease
Feat.
S. Winder
29:43
Michigan Medicine
GI and Hepatic Complications of Cancer Immunotherapy
Feat.
R. Fontana
12:33
UCLA Health
Long Term Management of Liver Transplant Recipients
Feat.
G. Choi
19:45
Houston Methodist Hospital
Alcoholism is a Mid-brain Disease: Treat it as Such
Feat.
H. Wetsman
49:14
Scripps Health
Using Resmetirom (THR-β Agonist) in Your Practice for MASH
Feat.
J. Gutierrez
48:59
Northwestern Medicine Gastroenterology
Cutting Edge Diagnostics and Treatment for NAFLD
Feat.
M. E. Rinella,
L. Van Wagner
44:20
UCSF School of Medicine
Alcohol Use Disorder
Feat.
T. Defries
27:35
Yale School of Medicine
Fatty Liver Disease: When to Refer?
21:35
Keck School of Medicine of USC
Mock Tumor Board: Liver Masses
Feat.
J. Kahn,
A. Ahearn
25:53
Houston Methodist Hospital
Non-Alcoholic Fatty Liver Disease: Where Are We in 2023?
Feat.
N. Gunn
24:30
Scripps Health
Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease
Feat.
J. Au
21:10
Cedars Sinai
Immune Checkpoint Inhibitor-Induced Hepatitis
Feat.
Y. Wang
22:23
Pennsylvania Society of Gastroenterology
Updates on Management of NASH
Feat.
T. Singh
60:40
Scripps Health
Primary Care Management of Chronic Liver Disease
Feat.
J. Gutierrez
22:31
University of California, Irvine (UCI) Health 14th Annual Orange County Symposium for Cardiovascular Disease Prevention
Non-Alcoholic Fatty Liver Disease and Cardiovascular Risks: A Scient…
Feat.
P. Duell
26:11
Scripps Health
New Treatments of Nonalcoholic Steatohepatitis (NASH): An Update on …
Feat.
J. Frias
